Johnson & Johnson has agreed to acquire Austin-based Ollin Biosciences for $2.2 billion upfront, while Blackstone Life Sciences plans $750 million in separate clinical-trial funding. Announced November 16, 2026, the agreements center on an experimental treatment for retinal disease. The figures, early study findings and closing conditions explain the deal’s scope.
Key Takeaways
- Johnson & Johnson agreed to pay $2.2 billion upfront for Ollin Biosciences
- Additional acquisition payments could reach approximately $1.125 billion if specified milestones are met
- Blackstone plans $750 million in separate funding for Phase 3 development of OLN324, contingent on closing
- A 164-patient Phase 1b study reported early findings that require confirmation in larger trials
Johnson & Johnson’s proposed purchase brings Ollin’s lead candidate, OLN324, into the pharmaceutical company’s development plans. The drug is being studied for wet age-related macular degeneration and diabetic macular edema, two conditions associated with damage to central vision.
A $2.2 Billion Upfront Price Carries Conditional Payments
Johnson & Johnson announced the definitive agreement on November 16. Its stated purchase terms include $2.2 billion upfront and up to approximately $1.125 billion in additional regulatory and commercial milestone payments, putting the maximum potential acquisition consideration at about $3.325 billion.
The additional amount is conditional. It would become payable only if the specified milestones are achieved, and it should not be treated as part of the guaranteed upfront price.
Ollin’s programs would expand Johnson & Johnson’s activities beyond its established vision products into retinal drug development.
Other recent U.S. healthcare transactions have involved different capabilities. GE HealthCare’s SOFIE acquisition agreement concerns radiopharmaceutical manufacturing and distribution, while the proposed Ollin deal centers on an experimental therapy.
Blackstone’s $750 Million Agreement Covers Phase 3 Testing
Blackstone Life Sciences has separately agreed to provide Johnson & Johnson with $750 million over several years to finance Phase 3 development of OLN324. That arrangement depends on the Ollin acquisition closing and is not an additional payment by Johnson & Johnson to Ollin shareholders.
In return, Blackstone would qualify for certain regulatory and sales milestone payments and royalties at single-digit rates. The parties have not publicly specified the exact royalty percentage or the amounts of every potential payment.
The separate arrangement covers clinical testing rather than the purchase price. The drug’s regulatory and commercial outcomes remain uncertain.
The acquisition is expected to close before year-end, subject to regulatory approvals and other customary conditions.
JADE Trial Data Show a 93% Retreatment-Free Rate in One Group
OLN324 targets two proteins associated with retinal fluid leakage: vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2). It is administered by injection into the eye.
“OLN324 selectively targets two important drivers of retinal disease,” said Kip Connor, a Johnson & Johnson ophthalmology executive, when the agreement was announced. The drug is still investigational, and claims about longer intervals between treatments require further clinical testing.
Ollin’s randomized Phase 1b JADE study enrolled 164 U.S. patients with wet age-related macular degeneration or diabetic macular edema. Participants received three monthly doses of OLN324 or the established medicine faricimab, sold as Vabysmo, followed by 12 weeks during which additional treatment was permitted under specified rules.
In the diabetic macular edema group, Ollin reported that 93% of patients assigned to OLN324 at 4 milligrams completed the observation period without another injection, compared with 89% in the faricimab group. The company also reported greater average reductions in retinal thickness for some OLN324 recipients.
For wet age-related macular degeneration, Ollin described retinal-thickness improvements as broadly comparable between the treatments. The data were early-stage and company-reported, rather than proof that OLN324 would outperform available medicines in larger studies.
Ollin’s Growth and Regulatory Work Preceded the Deal
Ollin was founded in Austin in 2023 and publicly announced a $330 million Series B financing round on June 24, 2026. The company said the funding would support global Phase 3 trials of OLN324, along with a separate experimental program targeting thyroid eye disease.
Before announcing the acquisition, Ollin said it had completed an end-of-Phase 2 meeting with the U.S. Food and Drug Administration and received scientific advice from the European Medicines Agency. Those interactions concern study planning and do not constitute regulatory approval of OLN324.
The antibody was discovered by Innovent Biologics and has been developed in collaboration with Ollin. Jason S. Ehrlich, MD, PhD, is Ollin’s co-founder and chief executive, and the company identified Goldman Sachs and Centerview Partners as financial advisers on the sale.
The agreement takes place as other pharmaceutical companies pursue U.S. operational expansion. Bristol Myers Squibb’s Houston plans concern a proposed facility, a separate type of business commitment from Johnson & Johnson’s clinical-stage acquisition.
Frequently Asked Questions
How much is Johnson & Johnson paying for Ollin Biosciences?
Johnson & Johnson agreed to pay $2.2 billion upfront. Up to approximately $1.125 billion more could become payable if specified regulatory and commercial milestones are met.
What is OLN324 being developed to treat?
OLN324 is being studied for wet age-related macular degeneration and diabetic macular edema. It is an experimental antibody targeting VEGF and Ang2, and it has not received approval for these uses.
What role does Blackstone have in the transaction?
Blackstone Life Sciences plans to provide $750 million over multiple years for Phase 3 development of OLN324 after the acquisition closes. It would be eligible for certain milestone payments and single-digit royalties in return.
When is the Ollin acquisition expected to close?
Johnson & Johnson expects closing before the end of 2026. Completion depends on regulatory approvals and other customary conditions, so the date is not guaranteed.



